Toll-like receptor 9 (TLR9) blocking agent and application thereof
A blocker and receptor technology, applied in the direction of anti-inflammatory agents, non-central analgesics, medical preparations containing active ingredients, etc., can solve the problems of ambiguity, no effect, difference in effect intensity, etc., and achieve wide application Foreground, clear target, high blocking activity effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0030] Example 1 CpG-ODN-like TLR9 blocking agent example and preparation
[0031] 1.1 Blocker name: C41
[0032] Sequence structure: TGGCGCGCACCCACGGCCTG
[0033] 1.2 Blocker name: C32
[0034] Sequence structure: CTTCGCGTTAGCGTTGAGTG
[0035] 1.3 Blocker name: C35
[0036] Sequence structure: TTGCGCGCCCTCCATCGAGG
[0037] The above three CpG-ODN-like TLR9 blockers all have the structural features described in the invention, that is, they have a CGCG core structure at the 4th to 7th positions, but the flanking sequences are different, and all have similar blocking effects. Its preparation method is to chemically synthesize all thionucleotide fragments (entrusted to Shanghai Sangon Biological Co., Ltd. to synthesize), and the synthesis amount of each of the above blockers is 30OD.
Embodiment 2
[0038] Determination of the Effect of Example 2 CpG-ODN-like TLR9 Blocker on Cell Viability (MTT Method)
[0039] 2.1 Main materials, reagents and equipment:
[0040] 1) MTT reagent: Sigma, Inc. USA.
[0041] 2) DMEM culture fluid (1L / bag), Gibco, Inc.USA.
[0042] 3) Dimethyl sulfoxide, Chongqing Chuandong Chemical (Group) Co., Ltd.
[0043] 4) Microplate reader: Bio-RAD Model 550.
[0044] 5) Cell incubator: FORMA 3111.
[0045] 6) RAW264.7 cell line: ATCC, USA.
[0046] 7) (Healthy) human peripheral blood macrophages: provided by Southwest Hospital Blood Bank
[0047] 2.2 Experimental method: Using blue tetrazolium thiazolium (MTT) method, the mouse RAW264.7 cells and human peripheral blood macrophages were diluted to 1×10 with DMEM medium, respectively. 6 / mL, added to a 96-well plate (200 μL / well), placed at 37 ° C, 5% CO 2 After culturing in the incubator for 2 hours, the three blocking agents C41, C32, and C35 were respectively set up as experimental groups at di...
Embodiment 3
[0049] Example 3: Effects of CpG-ODN-like TLR9 blockers on the release of TNF-α from RAW264.7 cells and human peripheral blood macrophages induced by stimulating molecules
[0050]3.1 Main materials, reagents and equipment:
[0051] 1) DMEM culture medium (1L / bag), Gibco, Inc.USA.
[0052] 2) Human TNF-αELISA Kit, eBioscience, Inc.USA.
[0053] 3) Mouse TNF-αELISA Kit, eBioscience, Inc.USA.
[0054] 4) Microplate reader: Bio-RAD Model 550.
[0055] 5) Cell incubator: FORMA 3111.
[0056] 6) RAW264.7 cell line: ATCC, USA.
[0057] 7) (Healthy) human peripheral blood macrophages: provided by Southwest Hospital Blood Bank
[0058] 3.2 Experimental method: Dilute mouse RAW264.7 cells and human macrophages to 1×10 in DMEM medium 6 / mL, were added to 96-well plates (200 μL / well, each experimental group was 4 duplicate wells), at 37 ° C, 5% CO 2 After incubation for 2 h under the same conditions, after the cells adhered to the wall, the supernatant of the cells was replaced wi...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com